(Q37256499)

19 August 2017

1 reference

title

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice (English)

1 reference

19 August 2017

1 reference

1 reference

Laurent Becquemont

1

1 reference

19 August 2017

publication date

30 August 2008

1 reference

European Journal of Clinical Pharmacology

19 August 2017

published in

1 reference

19 August 2017

volume

64

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

953-960

1 reference

Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics

19 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-008-0542-2

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

21 January 2018

1 reference

12 December 2020

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

1 reference

12 December 2020

Drug hypersensitive syndrome caused by fluindione

1 reference

12 December 2020

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

1 reference

12 December 2020

The largest prospective warfarin-treated cohort supports genetic forecasting

1 reference

12 December 2020

Use of genetic and nongenetic factors in warfarin dosing algorithms

1 reference

12 December 2020

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

12 December 2020

Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations

1 reference

12 December 2020

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

1 reference

12 December 2020

Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population

1 reference

12 December 2020

Determination of bleeding risk using genetic markers in patients taking phenprocoumon

1 reference

12 December 2020

Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).

1 reference

12 December 2020

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

1 reference

12 December 2020

Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California

1 reference

12 December 2020

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

1 reference

12 December 2020

Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose

1 reference

12 December 2020

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

1 reference

12 December 2020

Genetic determinants of response to warfarin during initial anticoagulation

1 reference

12 December 2020

Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe

1 reference

12 December 2020

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

1 reference

12 December 2020

Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes

1 reference

12 December 2020

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

1 reference

12 December 2020

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

1 reference

12 December 2020

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

1 reference

12 December 2020

A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk

1 reference

12 December 2020

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

1 reference

12 December 2020

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

12 December 2020

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

1 reference

12 December 2020

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

1 reference

12 December 2020

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers

1 reference

12 December 2020

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients

1 reference

12 December 2020

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism

1 reference

12 December 2020

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol

1 reference

12 December 2020

Acenocoumarol stabilization is delayed in CYP2C93 carriers

1 reference

12 December 2020

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

1 reference

12 December 2020

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

1 reference

12 December 2020

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

1 reference

12 December 2020

Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes

1 reference

12 December 2020

Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

1 reference

12 December 2020

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

1 reference

12 December 2020

Genetic and environmental risk factors for oral anticoagulant overdose

1 reference

12 December 2020

Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.

1 reference

12 December 2020

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

1 reference

12 December 2020

Development of a Contemporary Bleeding Risk Model for Elderly Warfarin Recipients

1 reference

12 December 2020

CYP4F2 genetic variant alters required warfarin dose

1 reference

12 December 2020

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.

1 reference

12 December 2020

Worldwide management of oral anticoagulant therapy: the ISAM study

1 reference

12 December 2020

Pharmacogenetics of acenocoumarol pharmacodynamics.

1 reference

12 December 2020

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

1 reference

12 December 2020

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

1 reference

12 December 2020

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

1 reference

12 December 2020

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

1 reference

12 December 2020

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

1 reference

12 December 2020

The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol

1 reference

12 December 2020

Association of warfarin dose with genes involved in its action and metabolism

1 reference

12 December 2020

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

1 reference

12 December 2020

The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients

1 reference

12 December 2020

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

1 reference

12 December 2020

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

12 December 2020

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

1 reference

12 December 2020

Identification of the gene for vitamin K epoxide reductase

1 reference

12 December 2020

10.1007/S00228-008-0542-2

Identifiers

DOI

1 reference

19 August 2017

1 reference